All In Biotech

Drug Trial Radar · NCT04549207

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

A Randomised Trial Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (REaCT-Hold BMA)

Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

240

Actual

Start

Oct 9, 2020

Primary completion

Apr 17, 2025

Study completion Sep 2026

Sponsor

Lead sponsor
Ottawa Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators propose to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA treatment in patients with bone metastases from breast cancer and castration-resistant prostate cancer

Conditions

  • Breast Cancer
  • Castration-resistant Prostate Cancer

Interventions

  • Bone modifying agentDrug

    Use of bone modifying agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Health related quality of life scoresTime frame: 48 weeks after randomization (one year of treatment)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • William Osler Health System

    Brampton, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Southlake Regional Health Centre

    Newmarket, Ontario, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Thunder Bay Regional Health Sciences Centre

    Thunder Bay, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.